Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GNA15 | P30679 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971865 | 0.86 | FFAR1 (0.56) | FFAR1FFAR4 | |
| SCHEMBL4971788 | 0.84 | FFAR1 (0.58) | FFAR1FFAR4 | |
| SCHEMBL2084534 | 0.84 | FFAR1 (0.49) | FFAR1FFAR4PTGER3PTGER1PTGER4 | |
| SCHEMBL4972553 | 0.81 | FFAR1 (0.48) | FFAR1FFAR4PTGER3PTGER1PTGER4 | |
| SCHEMBL4970369 | 0.81 | FFAR1 (0.51) | FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL4970681 | 0.81 | FFAR4 (0.52) | FFAR1FFAR4MEN1RAB9AKMT2A | |
| SCHEMBL4969518 | 0.81 | FFAR4 (0.47) | FFAR1FFAR4PTGER3PTGER1PTGER4 | |
| SCHEMBL4971028 | 0.80 | FFAR1 (0.54) | FFAR1FFAR4 | |
| SCHEMBL4969467 | 0.80 | MEN1 (0.54) | FFAR1FFAR4MEN1KMT2A | |
| SCHEMBL4968600 | 0.79 | FFAR1 (0.50) | FFAR1FFAR4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781274-B1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-11-05 | — | — | EP | claimed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | claimed |
| EP-1781274-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | claimed |
| WO-2006018325-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | claimed |
| EP-1781274-B1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-11-05 | — | — | EP | disclosed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | FFAR1 13/4885FFAR4 36/4885PTGER3 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.